More about

Lymphoma

News
April 12, 2022
3 min read
Save

New COVID-19 vaccine may protect patients with B-cell deficiencies

New COVID-19 vaccine may protect patients with B-cell deficiencies

CoVac-1, a COVID-19 vaccine, induced T-cell responses in patients with B-cell deficiencies, including those with lymphoma and leukemia, according to study results presented during American Association for Cancer Research Annual Meeting.

News
April 10, 2022
3 min read
Save

Immunotherapy combination shows ‘remarkable’ activity for patients with advanced lymphoma

Immunotherapy combination shows ‘remarkable’ activity for patients with advanced lymphoma

Natural killer cells combined with a bispecific antibody induced response among nearly 90% of patients with relapsed or refractory CD30-positive lymphoma, according to phase 1/phase 2 trial results.

News
April 09, 2022
2 min read
Save

Point-of-care CAR-T shows ‘promising’ efficacy, safety for B-cell non-Hodgkin lymphoma

Point-of-care CAR-T shows ‘promising’ efficacy, safety for B-cell non-Hodgkin lymphoma

Early phase 1 trial results using an investigational chimeric antigen receptor T-cell therapy manufactured at University of Colorado show encouraging efficacy for adults with relapsed or refractory B-cell non-Hodgkin lymphoma.

News
April 04, 2022
4 min read
Save

FDA approves Yescarta as second-line therapy for large B-cell lymphoma

FDA approves Yescarta as second-line therapy for large B-cell lymphoma

The FDA approved axicabtagene ciloleucel as second-line treatment for adults with large B-cell lymphoma who are refractory to first-line chemoimmunotherapy or experienced disease relapse within 12 months of initial treatment.

News
March 23, 2022
4 min read
Save

Investigational therapy for B-cell malignancies offers three targets in one CAR T cell

Investigational therapy for B-cell malignancies offers three targets in one CAR T cell

B-cell activating factor is a ligand protein, which makes it uniquely suited as a therapeutic option for the newly emerging class of multitargeted chimeric antigen receptor T-cell therapies.

News
March 21, 2022
3 min read
Save

Early intrathecal therapy shows promise for managing neurotoxicity related to CAR-T

Early intrathecal therapy shows promise for managing neurotoxicity related to CAR-T

Early intrathecal therapy effectively resolved symptoms related to high-grade neurotoxicity among patients who received chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma, according to a research letter in JAMA Oncology.

News
March 02, 2022
2 min read
Save

Three-drug regimen may reduce relapse risk after transplant for T-cell malignancies

Three-drug regimen may reduce relapse risk after transplant for T-cell malignancies

Adding romidepsin to busulfan and fludarabine reduced incidence of relapse among patients receiving allogeneic stem cell transplant for aggressive T-cell malignancies, according to results of a phase 1/phase 2 study.

News
February 28, 2022
3 min read
Save

Researchers develop test to predict durable remissions after CAR-T for lymphoma

Researchers develop test to predict durable remissions after CAR-T for lymphoma

Researchers have developed a novel quantitative assay that can predict which patients will achieve durable remissions after CD19-directed chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.

News
February 28, 2022
1 min read
Save

University of Utah Health appoints radiation oncology department chair

University of Utah Health appoints radiation oncology department chair

Amit Maity, MD, PhD, has been appointed chair of the department of radiation oncology for Spencer Fox Eccles School of Medicine at University of Utah.

News
February 27, 2022
2 min read
Save

ASH announces 2022 Scholar Award recipients

ASH announces 2022 Scholar Award recipients

ASH announced the 36 recipients of the society’s 2022 Scholar Awards.

View more